These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10874283)

  • 1. Highlights from the American College of Cardiology 49th Annual Scientific Sessions: March 12 to 15, 2000.
    McGuire DK; O'shea JC; Dyke CK; Kandzari DE; East MA; Tolleson TR
    Am Heart J; 2000 Jul; 140(1):181-8. PubMed ID: 10874283
    [No Abstract]   [Full Text] [Related]  

  • 2. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
    O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
    Kaul U; Gupta RK; Haridas KK; Ramesh SS; Sethi KK; Singh B; Agarwal R; Yadave RD; Ghose T; Sapra RR; Bajaj R; Shahi M; Bhagwat A; Kumar P; Mathews OP; Soni PK;
    Catheter Cardiovasc Interv; 2002 Dec; 57(4):497-503. PubMed ID: 12455085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet glycoprotein IIb/IIIa blockade with eptifibatide in angioplasty followed by stent implantation at 6 month in the ESPRIT study].
    Fresco C
    Ital Heart J Suppl; 2001 Sep; 2(9):1029-30. PubMed ID: 11675826
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.
    Marsh JD
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S15-26. PubMed ID: 12434711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using eptifibatide in patients undergoing coronary angioplasty with acute myocardial infarction.
    Wong CB
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):423-4; author reply 424. PubMed ID: 14571498
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?
    Kleiman NS
    Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):344-5. PubMed ID: 16265559
    [No Abstract]   [Full Text] [Related]  

  • 19. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
    O'Shea JC; Tcheng JE
    Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.
    Gibson CM; Kirtane AJ; Murphy SA; Rohrbeck S; Menon V; Lins J; Kazziha S; Rokos I; Shammas NW; Palabrica TM; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):668-75. PubMed ID: 16996831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.